Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why [Yahoo! Finance]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Yahoo! Finance
Currently, Iovance has two cancer drugs in its portfolio — Amtagvi and Proleukin. While Proleukin is approved to treat two cancer indications, namely metastatic renal cell carcinoma (mRCC) and metastatic melanoma, Amtagvi is approved for advanced melanoma indication. The company is developing its pipeline candidates, consisting of tumor-infiltrating lymphocyte (TIL), across multiple oncology indications. Year to date, Iovance's shares have soared 66.4% against the industry's 5.7% fall. Image Source: Zacks Investment Research This upside is attributable to the recent FDA approval for Amtagvi, granted under the accelerated pathway to treat advanced melanoma in patients previously treated with a PD-1 and targeted therapy. Following this approval, the drug is the first individualized, one-time cell therapy for melanoma patients. Prior to Amtagvi's accelerated approval, there were no FDA-approved therapies for advanced melanoma, which progressed on or after prior anti-PD-1/L1 th
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- Where Will Iovance Biotherapeutics Stock Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
- 3 Millionaire-Maker Biotech Stocks [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual MeetingGlobeNewswire
- These Biotech Stocks Could Soar 120% and 295%, According to Wall Street [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- 4/17/24 - Form 4
- IOVA's page on the SEC website